Association of polymorphisms in dopamine D3 receptor gene with Childhood tourette syndrome and efficacy of aripiprazole
10.3760/cma.j.issn.1674-6554.2015.08.014
- VernacularTitle:阿立哌唑对儿童期抽动症疗效与多巴胺D3受体基因多态性的关联性
- Author:
Xinguo TAN
;
Minghu CUI
- Publication Type:Journal Article
- Keywords:
Childhood tourette syndrome;
Dopamine D3 receptor;
Gene polymorphism;
Therapeutic efficacy;
Aripiprazole
- From:
Chinese Journal of Behavioral Medicine and Brain Science
2015;24(8):726-729
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the association of polymorphisms in dopamine D3 receptor (DRD3) gene exon 1 Ser9Gly with childhood tourette syndrome and efficacy of aripiprazole in Chinese Han population.Methods Polymorphisms of Ser9Gly in DRD3 gene was genotyped by using Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP) in 158 tourette syndrome patients (study group) and 187 healthy controls (control group).Patients in study group were assessed with Yale global tic severity scale(YGTSS) at baseline and at the end of the 8th week of treatment to evaluate the efficacy of aripiprazole.Results (1) There were no significant differences in genotypic frequency and allelic frequency of Ser9Gly in DRD3 gene between study group and control group (P＞0.05).(2) Significant difference was found in frequency of Ser9Gly in DRD3 gene between effective and ineffective groups (genotype:Ser/Ser 40 vs 17;Ser/Gly 52 vs 28;Gly/Gly 7 vs 14;alle:Ser 132 vs 62;Gly 66 vs 56)(P＜0.05).(3) There were no significant differences in distribution of genotypes and alleles of Ser9Gly among three-type of tourette syndrome (P＞0.05).Conclusion The polymorphisms of Ser9Gly in DRD3 gene are associated with the efficacy of aripiprazole.
